Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody - Hopkins, Paul N.; Defesche, Joep; Fouchier, Sigrid W.; Bruckert, Eric; Luc, Gérald; Cariou, Bertrand; Sjouke, Barbara; Leren, Trond P.; Harada-Shiba, Mariko; Mabuchi, Hiroshi; Rabès, Jean-Pierre; Carrié, Alain; et al. (Circulation. Cardiovascular genetics, 2015)
Keywords: Adolescent; Adult; Aged; Antibodies, Monoclonal - administration & dosage; Cholesterol, LDL - blood; Coronary Artery Disease - blood; Coronary Artery Disease - drug therapy; Coronary Artery Disease - genetics; Double-Blind Method; Female; Humans; Hyperlipoproteinemia Type II - blood; Hyperlipoproteinemia Type II - drug therapy; Hyperlipoproteinemia Type II - genetics; Male; Middle Aged; Mutation; Original; Proprotein Convertase 9; Proprotein Convertases - antagonists & inhibitors; Proprotein Convertases - genetics; Proprotein Convertases - metabolism; Serine Endopeptidases - genetics; Serine Endopeptidases - metabolism; PCSK9 protein; clinical trial; genetics; alirocumab; cardiovascular diseases; human; hypercholesterolemia